Business Wire

TELEROUTE

17.9.2020 10:02:04 CEST | Business Wire | Press release

Share
Teleroute, Part of Alpega Group, Confirms Robust Recovery of Freight Offers After Coronavirus Shock

The activity registered on the Teleroute Freight Exchange has been experiencing an upward trend for several weeks following the strong increase in demand for their solution during the Coronavirus crisis, demonstrating the resilience and anti-cyclical nature of one of Europe’s leading freight exchanges.

After the initial shock to the European market due to the Coronavirus, the Teleroute Freight Exchange, that together with 123Cargo and Wtransnet form one of the largest European transport collaboration networks, confirms the return of activity with a notable upturn in the number of freight offers in recent weeks , placing the activity at pre-coronavirus level and even higher in the last weeks of July, exhibiting none of the typical seasonal slowdown.

The most difficult moment for the transportation industry due to the crisis took place in April, where the complete stoppage of industrial activity throughout Europe caused freight volume to drop dramatically. This period was then followed by a second disrupted supply chain period where freight forwarders and carriers, looking for new routes for new volumes, turned to Teleroute to manage demand and the number of new users on Teleroute grew by 1,200.

Speaking about this trend, Fabrice Douteaud, COO of Teleroute, said: “We are very proud of the resilience shown by the transport & freight forwarding companies by continuing their important work during these very difficult times. We have experienced an exceptional demand for our freight exchange during this crisis, a proof of the value we bring to the market: facilitating the collaboration of transport professionals.”

France, the driving force behind the recovery of freight offers in Europe

After the month of April with volume below average, we are in the middle of the summer with a very notable recovery of the freight offers on Teleroute with France as the country of origin, which has doubled.

This leaves us with an activity in July that has far exceeded the monthly average number of published freight offers, mainly in the domestic market (90% of volumes) and in exports to Belgium, Germany and Spain in equal parts.

On the other hand, if we look at imports, the numbers are even better, in the last two months we find volumes well above the usual and that shows the recovery of the main countries that send merchandise to France: Italy, which leads the ranking with 37% of freight offers; Germany (29%), Belgium (23%) and Spain (7%).

Italy doubles its transport activity in July thanks to exports

Regarding the data obtained from the freight offers published on Teleroute originating in Italy, one of the countries most affected by the pandemic, we find a surprising recovery in July where the volume has doubled thanks to the reactivation of transactions with France, which account for 57% of Italian exports. Germany with 18% and Spain with 15% close the top 3.

In relation to inbound freight, the transalpine country doubled the number of import offers in July compared to previous months, placing activity above the average in 2019 and only slightly lower than the months with the highest activity on the freight exchange. A comeback led by the flow of goods with France, with 40% of the freight offers published, and Germany (15%) as the main countries offering freight to the Italian market.

Huge growth in the German domestic transport market

Focusing on Germany , another of the European economy's main drivers, we observed a strong rebound in activity in July with 25% above the monthly average in 2019, the domestic market's upward growth, which was already palpable in June, and accounting for 50% of the freight offers with Germany as origin and/or destination.

The other freight offers, are divided into 28% imports, mainly from Italy and France, and exports (remaining 22%) whose main destinations are France and the Netherlands.

Numbers that, in accordance with the offers registered in Teleroute, place the European transport market that Teleroute serves, already back to normal in practically the entire region and, on the current trajectory, will be performing ahead of 2019 for the remainder of the year.

Alpega Group

End-to-End Transportation software

Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.

Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123Cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.

These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. All of Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs 500 people with 31 different nationalities.

More information can be found at www.alpegagroup.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye